LAM
ALXN

Lebenthal Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Lebenthal Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$3.33M Buy
27,468
+197
+0.7% +$25.4K 0.41% 74
2016
Q4 		$3.34M Sell
27,271
-3,400
-11% -$416K 0.43% 68
2016
Q3 		$3.76M Hold
30,671
– – 0.49% 55
2016
Q2 		$3.58M Buy
+30,671
New +$4.35M 0.46% 62

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Lebenthal Asset Management's ALXN Position: Q1 2017 in Review

Lebenthal Asset Management increased its Alexion Pharmaceuticals (ALXN) stake by 0.72% in Q1 2017, buying an estimated $25.4K and bringing the position to 27,468 shares worth $3.33M. The position accounts for 0.41% of the portfolio, ranked #74.

Lebenthal Asset Management first reported a position in ALXN in Q2 2016 and has held it in 4 quarters since. The position peaked at $3.76M in Q3 2016. 561 funds tracked by Wall St. Rank hold ALXN as of Q1 2017.

  • Lebenthal Asset Management held 27,468 shares of Alexion Pharmaceuticals worth $3.33M as of Q1 2017.
  • Lebenthal Asset Management bought 197 Alexion Pharmaceuticals shares in Q1 2017, an estimated $25.4K.
  • Alexion Pharmaceuticals made up 0.41% of Lebenthal Asset Management's portfolio in Q1 2017, its #74 holding.
  • Lebenthal Asset Management first reported a position in Alexion Pharmaceuticals in Q2 2016 and has held it in 4 quarters since.
  • Lebenthal Asset Management's Alexion Pharmaceuticals position peaked at $3.76M in Q3 2016.
  • 561 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2017.

Based on Lebenthal Asset Management's 13F filing for Q1 2017, filed 15 May 2017.